GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Regencell Bioscience Holdings Ltd (NAS:RGC) » Definitions » Cash Ratio

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Cash Ratio : 19.05 (As of Jun. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Regencell Bioscience Holdings Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Regencell Bioscience Holdings's Cash Ratio for the quarter that ended in Jun. 2023 was 19.05.

Regencell Bioscience Holdings has a Cash Ratio of 19.05. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Regencell Bioscience Holdings's Cash Ratio or its related term are showing as below:

RGC' s Cash Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.12   Max: 28.4
Current: 19.05

During the past 5 years, Regencell Bioscience Holdings's highest Cash Ratio was 28.40. The lowest was 0.01. And the median was 0.12.

RGC's Cash Ratio is ranked better than
98.54% of 1027 companies
in the Drug Manufacturers industry
Industry Median: 0.58 vs RGC: 19.05

Regencell Bioscience Holdings Cash Ratio Historical Data

The historical data trend for Regencell Bioscience Holdings's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regencell Bioscience Holdings Cash Ratio Chart

Regencell Bioscience Holdings Annual Data
Trend Jun19 Jun20 Jun21 Jun22 Jun23
Cash Ratio
0.12 0.12 0.01 28.40 19.05

Regencell Bioscience Holdings Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Cash Ratio Get a 7-Day Free Trial Premium Member Only 0.01 - 28.40 - 19.05

Competitive Comparison of Regencell Bioscience Holdings's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Regencell Bioscience Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regencell Bioscience Holdings's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Regencell Bioscience Holdings's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Regencell Bioscience Holdings's Cash Ratio falls into.



Regencell Bioscience Holdings Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Regencell Bioscience Holdings's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.565/0.607
=19.05

Regencell Bioscience Holdings's Cash Ratio for the quarter that ended in Jun. 2023 is calculated as:

Cash Ratio (Q: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.565/0.607
=19.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Regencell Bioscience Holdings  (NAS:RGC) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Regencell Bioscience Holdings Cash Ratio Related Terms

Thank you for viewing the detailed overview of Regencell Bioscience Holdings's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regencell Bioscience Holdings (Regencell Bioscience Holdings) Business Description

Traded in Other Exchanges
N/A
Address
29 Leighton Road, 9/F Chinachem Leighton Plaza, Causeway Bay, Hong Kong, HKG
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.

Regencell Bioscience Holdings (Regencell Bioscience Holdings) Headlines

From GuruFocus